Pfizer in the news

A viral video misrepresented Pfizer CEO's statement about reducing the number of people who cannot afford medicines.

FDA approved Pfizer's updated COVID vaccine for vulnerable groups, extending its COVID relevance but with limited impact on overall revenue amid ongoing oncology growth and regulatory risks.

Pfizer's shares rose modestly with light options trading, lower implied volatility, and increased demand for downside protection.

Moderna's stock rose significantly ahead of the full release of its Phase 3 melanoma vaccine data, while BioNTech showed a slight gain and Pfizer declined.

Florida Attorney General James Uthmeier has filed a lawsuit against Pfizer over alleged misleading claims about its COVID-19 vaccine.

Pfizer's board of directors declared a $0.43 per share fourth-quarter 2026 cash dividend, payable December 7, 2026.

Novavax stock dropped after health officials declared the Siberian plague risk low, impacting vaccine stocks including Moderna and Pfizer.

Pfizer's high dividend yield is sustainable due to strong cash flow, but future growth is uncertain due to patent expirations and high debt from past acquisitions.

Vaxcyte's VAX-31 pneumococcal vaccine achieved strong Phase 3 trial results, outperforming Pfizer's Prevnar 20 and Merck's Capvaxive on certain serotypes, indicating significant market potential.

Pfizer's stock is an underrated dividend investment due to its sustainable high yield, low valuation, and extensive drug pipeline, despite recent underperformance and restructuring challenges.

Pfizer is making strategic acquisitions and heavily investing in oncology R&D to offset impending patent expirations and drive future revenue growth, despite short-term challenges.

Pfizer Inc. stock underperformed its competitors on Friday.

Pfizer's Litfulo demonstrated significant repigmentation in vitiligo patients during phase 3 trials.

Pfizer faces a lawsuit from Florida concerning its COVID-19 vaccine claims, while simultaneously releasing positive Phase 2 data for its new eczema drug, tilrekimig.

A comparison of Novo Nordisk and Pfizer's financials, risks, and valuations concludes Pfizer is a better investment for 2026 due to its lower entry point and improving net income.

Pfizer faces a lawsuit from Florida over its COVID-19 vaccine marketing while simultaneously reporting positive Phase 2 results for its eczema drug, tilrekimig, which is now in Phase 3 trials against Dupixent.

Pfizer's stock decline and high dividend yield are influenced by reduced COVID-19 product demand and patent expirations, while strategic acquisitions and pipeline development aim to rejuvenate its growth.

Pfizer announced positive Phase 3 results for its oral drug Litfulo in treating vitiligo and favorable Phase 2 data for tilrekimig in atopic dermatitis, with plans for regulatory submissions and expansion into respiratory conditions.

Pfizer is shifting its focus from past acquisitions to future growth drivers like obesity drugs and AI, despite flat revenues and future growth dependent on unlaunched products.

Florida has sued Pfizer and its CEO, alleging deceptive marketing of its COVID-19 vaccine, with Pfizer denying the claims.